Bristol-Myers Squibb and GeneCentric ally on biomarker research

Bristol-Myers Squibb has announced a new collaboration with GeneCentric Diagnostics in the field of biomarker research.

The alliance aims to determine whether the application of GeneCentric's Cancer Subtype Platform (CSP) could be useful in identifying translational biomarkers for Bristol-Myers Squibb's Opdivo, which may help to inform future clinical trials.

CSP is designed to isolate biologic subtypes of cancer through the integrated analysis of tumour genomics, allowing researchers to select biomarkers that can identify the patients who are best suited to treatment with certain compounds.

GeneCentric has also secured equity funding from Bristol-Myers Squibb to support the clinical development of the CSP platform, as well as to finance the building-out of GeneCentric's new laboratory in Research Triangle Park.

Dr Fouad Namouni, head of oncology development at Bristol-Myers Squibb, said: "We are very pleased to support GeneCentric's long-term goals as a company and to explore the application of its technology towards more targeted approaches to help patients."

This comes as part of a broader commitment by Bristol-Myers Squibb to further its understanding of immuno-oncology medicines to produce therapies for hard-to-treat cancers.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.